Compare Novo Nordisk A/S (NVO) vs Ross Stores, Inc. (ROST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novo Nordisk A/S vs Ross Stores, Inc. — how do they compare? Novo Nordisk A/S trades at $38.45 (market cap $165.31B), while Ross Stores, Inc. trades at $223 (market cap $71.94B). The key difference: Novo Nordisk A/S is far larger — about 2.3× Ross Stores, Inc.'s market cap, and Novo Nordisk A/S pays the higher dividend (4.71%). Which is the better fit depends on your goals — on Pluang, investors hold Novo Nordisk A/S for 116 Days and Ross Stores, Inc. for 48 Days on average.
| NVO | ROST | |
|---|---|---|
Market Cap | $165.31B | $71.94B |
Volume | 11,432,838 | 2,002,519 |
Sector | Health | Consumer Cyclical |
52-Week High | $63.98 | $255.23 |
52-Week Low | $35.29 | $147.71 |
Typical Hold Time | 116 Days | 48 Days |
Enterprise Value | $179.56B | $72.39B |
Dividend Yield | 4.71% | 0.79% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novo Nordisk (NVO) trades at $38.41, up 0.38% with strong fundamentals including 35.35% net margin and consistent earnings beats. The stock shows bearish technical signals but maintains robust profitability with $102.43B net income. Recent news highlights pipeline developments including Wegovy pill data and FDA reviews, while competition with Eli Lilly intensifies in the obesity drug market.
NVO presents a compelling value opportunity with a 9.66 P/E ratio and 59% upside to the $44.67 consensus target. However, technical weakness and competitive pressures from Lilly's new drug candidates pose near-term risks. The company's strong cash flow generation and 59.82% ROE support long-term growth prospects despite regulatory uncertainties.
Ross Stores (ROST) trades at $222.41, down 1.38% amid broader market weakness. The stock shows strong fundamentals with consistent earnings beats (Q4 2025-Q2 2026) and robust profitability metrics including 42.63% ROE and 10.85% net margin. Technical indicators signal bearish momentum with the price near key support at $221, while analyst consensus remains bullish with a $274.14 price target. Recent news highlights store expansion initiatives and strong closeout supply positioning the company for growth.
ROST presents a compelling investment case with strong operational performance and analyst confidence, though near-term technical weakness and competitive pressures warrant caution. The 16% upside to consensus target offers potential reward, but investors should monitor execution of expansion plans and consumer spending trends given the bearish technical signals.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →About Ross Stores, Inc.
Ross Stores is a leading American off-price apparel and home fashion retailer, operating over 1,920 stores (at the end of fiscal 2021) across the Ross Dress for Less and dd's Discounts banners. Ross offers a variety of name-brand products and targets undercutting conventional retailers' regular prices by 20%-70%. The company uses an opportunistic, flexible merchandising approach
Read more on ROST →
